In this conversation between Rebecca Johnson, PhD, ACT EAB member and clinical research recruitment and inclusion executive ...
In today's ACT Brief, we examine leadership instability and regulatory uncertainty during Makary's FDA tenure, how lived ...
In today's ACT Brief, we examine cost models for imaging infrastructure in clinical trials, how community relationships ...
FDA Commissioner Marty Makary, MD, MPH, resigned Tuesday, according to The Associated Press, just 13 months after being ...
In this Q&A, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how clinical ...
For years, the clinical trial industry has been sold an appealing idea: participant adherence is largely a problem that can ...
Seventeen placebo-controlled trials across seven antibodies yielded statistically significant but clinically small mean effects on ADAS-Cog and CDR-SB, with low-to-moderate certainty and ...
In this video interview, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, explains why the most consequential shift in clinical trial design is not methodological ...
Signant’s acquisition of Ametris consolidates patient-reported outcomes and continuous wearable sensing into one workflow, reducing multi-vendor operational overhead and dataset reconciliation ...
In today's ACT Brief, we explore practical steps sponsors can take to prepare for the plausible mechanism framework, how behavioral science addresses root causes of recruitment and diversity ...
In this video interview, Mwango Kashoki, MD, MPH, senior vice president and global head of regulatory strategy at Parexel, outlines the steps sponsors can take today—from early FDA engagement and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results